CN102743378B - 一种含十八种氨基酸的组合物 - Google Patents
一种含十八种氨基酸的组合物 Download PDFInfo
- Publication number
- CN102743378B CN102743378B CN201210265091.2A CN201210265091A CN102743378B CN 102743378 B CN102743378 B CN 102743378B CN 201210265091 A CN201210265091 A CN 201210265091A CN 102743378 B CN102743378 B CN 102743378B
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- disodium edetate
- calcium disodium
- amino acids
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 24
- 229940024606 amino acid Drugs 0.000 claims abstract description 43
- 235000001014 amino acid Nutrition 0.000 claims abstract description 43
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 32
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960001305 cysteine hydrochloride Drugs 0.000 claims abstract description 27
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 17
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 17
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 17
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 17
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 17
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 17
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 17
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 17
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960000310 isoleucine Drugs 0.000 claims abstract description 17
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930182817 methionine Natural products 0.000 claims abstract description 17
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004474 valine Substances 0.000 claims abstract description 17
- 239000004471 Glycine Substances 0.000 claims abstract description 16
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 16
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 16
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 16
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 16
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000004473 Threonine Substances 0.000 claims abstract description 16
- 235000004279 alanine Nutrition 0.000 claims abstract description 16
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 16
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960005337 lysine hydrochloride Drugs 0.000 claims abstract description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 14
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 14
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000811 xylitol Substances 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 13
- 229960002675 xylitol Drugs 0.000 claims abstract description 13
- 235000010447 xylitol Nutrition 0.000 claims abstract description 13
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 12
- 229960003589 arginine hydrochloride Drugs 0.000 claims abstract description 12
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 15
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 15
- 235000013922 glutamic acid Nutrition 0.000 claims description 15
- 239000004220 glutamic acid Substances 0.000 claims description 15
- 229960003446 histidine monohydrochloride Drugs 0.000 claims description 11
- 239000008215 water for injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 abstract description 27
- 239000007924 injection Substances 0.000 abstract description 27
- -1 compound amino acid Chemical class 0.000 abstract description 20
- 230000003078 antioxidant effect Effects 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 14
- 239000003963 antioxidant agent Substances 0.000 abstract description 13
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 abstract 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 abstract 1
- 235000013921 calcium diglutamate Nutrition 0.000 abstract 1
- UMVAYAXXQSFULN-QHTZZOMLSA-L calcium;(2s)-2-aminopentanedioate;hydron Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O UMVAYAXXQSFULN-QHTZZOMLSA-L 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 17
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 238000001802 infusion Methods 0.000 description 10
- 239000003610 charcoal Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 235000010265 sodium sulphite Nutrition 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000031404 Chromosome Aberrations Diseases 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 231100000005 chromosome aberration Toxicity 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 229960002885 histidine Drugs 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- 229940105082 medicinal charcoal Drugs 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229920005549 butyl rubber Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 108091060290 Chromatid Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004756 chromatid Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 231100000188 sister chromatid exchange Toxicity 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910021655 trace metal ion Inorganic materials 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
检测项目 | 国家标准 | 0月 | 1月 | 2月 | 3月 | 6月 | 结论 |
性状 | 无色至微黄色 | 几乎无色 | 几乎无色 | 几乎无色 | 几乎无色 | 几乎无色 | 符合规定 |
PH值 | 5.0-6.2 | 5.6 | 5.6 | 5.6 | 5.6 | 5.6 | 符合规定 |
吸光度 | ≥95.0% | 98.8% | 98.6% | 98.2% | 98.1% | 97.8% | 符合规定 |
可见异物 | 应符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210265091.2A CN102743378B (zh) | 2012-07-30 | 2012-07-30 | 一种含十八种氨基酸的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210265091.2A CN102743378B (zh) | 2012-07-30 | 2012-07-30 | 一种含十八种氨基酸的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102743378A CN102743378A (zh) | 2012-10-24 |
CN102743378B true CN102743378B (zh) | 2013-07-24 |
Family
ID=47024112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210265091.2A Active CN102743378B (zh) | 2012-07-30 | 2012-07-30 | 一种含十八种氨基酸的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102743378B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103463013B (zh) * | 2013-09-22 | 2015-06-24 | 华仁药业股份有限公司 | 一种高浓度复合氨基酸注射液制备工艺 |
TW201932483A (zh) * | 2018-01-16 | 2019-08-16 | 林文欽 | 用於形成膠原蛋白的氨基酸組成物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102397245A (zh) * | 2011-11-05 | 2012-04-04 | 辽宁海神联盛制药有限公司 | 一种盐酸尼卡地平葡萄糖注射液 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1189167C (zh) * | 2002-03-06 | 2005-02-16 | 华瑞制药有限公司 | 复方氨基酸注射液及其制造方法 |
CN1615906A (zh) * | 2004-09-27 | 2005-05-18 | 俞锋 | 十八复方氨基酸注射液及其制备方法 |
CN101439036B (zh) * | 2008-12-22 | 2010-10-27 | 郑飞雄 | 一种含18种氨基酸的药物组合物 |
-
2012
- 2012-07-30 CN CN201210265091.2A patent/CN102743378B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102397245A (zh) * | 2011-11-05 | 2012-04-04 | 辽宁海神联盛制药有限公司 | 一种盐酸尼卡地平葡萄糖注射液 |
Also Published As
Publication number | Publication date |
---|---|
CN102743378A (zh) | 2012-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101439036B (zh) | 一种含18种氨基酸的药物组合物 | |
CN101439031B (zh) | 一种含18种氨基酸的药物组合物 | |
CN102743379B (zh) | 一种含十八种氨基酸的组合物及其制备方法 | |
EP2683361B1 (en) | Method for the preparaton of a levothyroxine solution | |
CN101357118B (zh) | 一种含15种氨基酸的药物组合物及其制备方法 | |
CN102091030A (zh) | 长春西汀注射液及其制备方法 | |
WO2016137969A2 (en) | Liquid levothyroxine formulations | |
CN102772360B (zh) | 一种兽用盐酸多西环素注射液及其制备方法 | |
CN102631665B (zh) | 一种丙氨酰谷氨酰胺注射液和复方氨基酸注射液的药物组合物 | |
CN101933922B (zh) | 一种含抗氧化剂的氨基酸组合物 | |
CN102743378B (zh) | 一种含十八种氨基酸的组合物 | |
CN102626409B (zh) | 一种含18种氨基酸的药物组合物 | |
CN100408032C (zh) | 一种稳定的多西他赛注射剂 | |
CN102872462B (zh) | 一种盐酸氨溴索组合物及其制剂 | |
CN102940628A (zh) | 一种复方氨基酸注射液及其制备方法 | |
CN103239442A (zh) | 复方氨基酸注射液(18aa-v)的制备方法 | |
CN105125480B (zh) | 一种硫辛酸的液体制剂及其制备方法 | |
CN103315997A (zh) | 一种含18种氨基酸的药物组合物 | |
CN107789317A (zh) | 一种硫辛酸注射液及制备方法 | |
CN102512360A (zh) | 稳定安全的供注射用托拉塞米药物组合物 | |
CN102895178A (zh) | 一种盐酸莫西沙星浓溶液型注射剂及其制备方法 | |
CN112999148A (zh) | 复方氨基酸组合物及其制备方法 | |
CN102600139B (zh) | 一种含20种氨基酸的药物组合物 | |
CN114306219B (zh) | 稳定的r-氯胺酮药物组合物 | |
CN108158989B (zh) | 一种盐酸氨溴索注射液组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121024 Assignee: Hubei Aerodurer Medical Instrument Co., Ltd. Assignor: Li Hui Contract record no.: 2014990000095 Denomination of invention: Composition containing eighteen amino acids Granted publication date: 20130724 License type: Common License Record date: 20140228 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121024 Assignee: Guangdong Litai Pharmaceutical Co., Ltd. Assignor: Li Hui Contract record no.: 2014990000105 Denomination of invention: Composition containing eighteen amino acids Granted publication date: 20130724 License type: Common License Record date: 20140303 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Guangdong Litai Pharmaceutical Co., Ltd. Assignor: Li Hui Contract record no.: 2014990000105 Date of cancellation: 20161209 |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20161209 Contract record no.: 2014990000095 License type after: Exclusive license License type before: General permission |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121024 Assignee: Guangdong Litai Pharmaceutical Co., Ltd. Assignor: Li Hui Contract record no.: 2017990000101 Denomination of invention: Composition containing eighteen amino acids Granted publication date: 20130724 License type: Common License Record date: 20170324 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20170322 Contract record no.: 2014990000095 License type after: General permission License type before: Exclusive license |
|
EM01 | Change of recordation of patent licensing contract | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20180125 Contract record no.: 2014990000095 Assignee after: Hubei long Du Le Pharmaceutical Co. Ltd. Assignee before: Hubei Aerodurer Medical Instrument Co., Ltd. |
|
EM01 | Change of recordation of patent licensing contract | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220509 Address after: 430073 No. 01, floor 6, unit 1, north main building, National Geospatial Information Industry base, No. 5-2, wudayuan Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province Patentee after: Wuhan Tian Tian medical science and Technology Co.,Ltd. Address before: 430071 1102, unit 2, building 6, Xinghai Hongcheng, No. 58, Minzhu Second Road, Hongshan District, Wuhan City, Hubei Province Patentee before: Li Hui |